TuisOGN • NYSE
add
Organon & Co
Vorige sluiting
$9,19
Dagwisseling
$9,28 - $9,64
Jaarwisseling
$8,01 - $23,10
Markkapitalisasie
2,49 mjd USD
Gemiddelde volume
7,48 m
P/V-verhouding
3,31
Dividend-opbrengs
0,84%
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,51 mjd | -6,72% |
Bedryfskoste | 516,00 m | -4,97% |
Netto inkomste | 87,00 m | -56,72% |
Netto winsgrens | 5,75 | -53,59% |
Wins per aandeel | 1,02 | -16,39% |
EBITDA | 409,00 m | -14,61% |
Effektiewe belastingkoers | 13,86% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 547,00 m | -4,87% |
Totale bates | 13,16 mjd | 10,64% |
Totale aanspreeklikheid | 12,61 mjd | 6,51% |
Totale ekwiteit | 542,00 m | — |
Uitstaande aandele | 259,96 m | — |
Prys om te bespreek | 4,38 | — |
Opbrengs op bates | 6,19% | — |
Opbrengs op kapitaal | 8,55% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 87,00 m | -56,72% |
Kontant van bedrywe | 75,00 m | -1,32% |
Kontant van beleggings | -172,00 m | -79,17% |
Kontant van finansiering | -75,00 m | -1,35% |
Netto kontantverandering | -128,00 m | -8,47% |
Beskikbare kontantvloei | -73,38 m | -288,75% |
Meer oor
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon produces all its products outside of the United States but gets a third of its revenue from the United States. Wikipedia
Gestig
1923
Webwerf
Werknemers
10 000
